Efficacy of GLP-1 Agonist Therapy in Autosomal Dominant WFS1-Related Disorder: A Case Report
- 19 October 2020
- journal article
- research article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 93 (6), 409-414
- https://doi.org/10.1159/000510852
Abstract
Background: Wolfram syndrome is a rare neurodegenerative disorder, characterized by the presence of diabetes insipidus, diabetes mellitus, optic atrophy, and sensorineural deafness. The majority of cases are due to autosomal recessive biallelic variants in the WFS1 gene; however, pathogenic autosomal dominant (AD) mutations have also been described. Glucagon-like peptide (GLP-1) agonists have been studied in both animal models and humans with classic Wolfram syndrome. Case: We present a 15-year-old female with a personal and family history of congenital strabismus, bilateral cataracts, low-frequency sensorineural hearing loss, and diabetes mellitus. Trio whole exome sequencing revealed a previously unknown maternally inherited heterozygous variant in exon 8 of the WFS1 gene c.2605_2616del12 p.Ser869_His872del, leading to the diagnosis of AD WFS1-related disorder. Treatment with a GLP-1 agonist resulted in marked improvement in glycemic control and discontinuation of insulin therapy. This patient’s response to a GLP-1 agonist provides suggestive indirect evidence for a role of WFS1 on β-cell endoplasmic reticulum stress and suggests that treatment with a GLP-1 agonist should be considered in patients with dominant forms of WS.Keywords
This publication has 23 references indexed in Scilit:
- Mutation update and uncommon phenotypes in a French cohort of 96 patients with WFS1‐related disordersClinical Genetics, 2014
- Autosomal Dominant Diabetes Arising From a Wolfram Syndrome 1 MutationDiabetes, 2013
- Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotypeGenetics in Medicine, 2013
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2aAmerican Journal of Physiology-Cell Physiology, 2013
- Endocrine and metabolic aspects of the Wolfram syndromeEndocrine, 2011
- Neurologic features and genotype‐phenotype correlation in Wolfram syndromeAnnals of Neurology, 2010
- Microvascular Diabetes Complications in Wolfram Syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness [DIDMOAD])Diabetes Care, 2007
- Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 geneJournal of Medical Genetics, 2005
- Morbidity and Mortality in the Wolfram SyndromeDiabetes Care, 1995